Search

Matthew J Rendo,1 Jacinth J Joseph,2 Liem Minh Phan,3 Christin B DeStefano4 1Department of Hematology/Oncology, Brooke Army Medical Center, San Antonio, TX, USA; 2Blood and Marrow Transplant Center, Methodist Le Bonheur Healthcare, Memphis, TN, USA; 3Clinical Investigation Facility, David Grant USAF Medical Center, Travis Air Force Base, CA, USA; 4Department of Hematology/Oncology, Walter Reed National Military Medical Center, Bethesda, MD, USACorrespondence: Christin B DeStefano, Email Christin.DeStefano@usuhs.eduAbstract: The therapeutic landscape of multiple myeloma (MM) has benefited from an emergence of novel therapies over the last decade. By inducing T-cell kill of target cancer cells, chimeric antigen receptor (CAR) T-cell therapies have improved outcomes of patients with hematologic malignancies. B-cell maturation antigen (BCMA) is the current target antigen of choice for most CAR T-cell products under investigation for MM. However, their shortcomings deal with logistical and clinical challenges, including limited availability, manufacturing times, and toxicities. This article provides an overview of recently developed and investigational CAR T-cell therapies for MM, highlighting current evidence and challenges.Keywords: multiple myeloma, CAR T-cell, immunotherapy